Is NTLA or NVAX more undervalued in 2026?

CirclFi compares Intellia Therapeutics, Inc. (NTLA) and Novavax, Inc. (NVAX) using 13 institutional-grade valuation models. NTLA has a Quality of Company score of 6.5/10 while NVAX scores 6.4/10.

Which is a better buy — NTLA or NVAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NTLA and NVAX valuations compare?

NTLA at $13.68 and NVAX at $10.32 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NTLA vs NVAX Valuation Comparison 2026 — Intrinsic Value Analysis

NTLA

Biotechnology

Intellia Therapeutics, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$13.68

Last close

Models

9/13

Active

NVAX

Biotechnology

Novavax, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$10.32

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	NTLA Fair Value	NTLA Upside	NVAX Fair Value	NVAX Upside
Bayesian DCF	Intrinsic	$4.02	-70.6%	$1.55	-84.9%
Earnings Power Value	Intrinsic	—	—	$2.46	-69.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.55	-95.5%	$2.92	-68.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NTLA vs NVAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NTLA vs NVAX — Which Stock Is More Undervalued?

NTLA scores higher with a 6.5/10 quality rating vs NVAX's 6.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intellia Therapeutics, Inc. (NTLA) and Novavax, Inc. (NVAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NTLA currently trades at $13.68 with a QOC of 6.5/10, while NVAX trades at $10.32 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).